Physician profile
Danielle Malbasa Rose
NPI 1871605303
$972.51
in general payments reported to CMS, 2019-2025
15 companies · $118 in 2025
The $118 reported for 2025 was more than what a typical Adolescent Medicine (Pediatrics) provider received nationally (typical 2025 total: $99.31).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $87.86 · 2021: $134 · 2022: $217 · 2023: $103 · 2024: $189 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $409.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $152.13 | 2019-2025 | Doc Band |
| Merck Sharp & Dohme LLC | $135.15 | 2019-2024 | Vaxelis, Gardasil 9, Gardasil |
| Pfizer INC. | $132.26 | 2019-2025 | |
| Corium, LLC | $105.04 | 2021-2024 | Azstarys |
| Tris Pharma INC | $104.95 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $95.21 | 2023-2024 | Jornay Pm |
| Sanofi Pasteur INC. | $57.69 | 2020-2025 | |
| Kaleo, INC. | $51.99 | 2020-2022 | |
| Neos Therapeutics, LP | $30.54 | 2020-2022 | |
| Phadia US INC. | $29.29 | 2019-2022 | |
| Ars Pharmaceuticals Operations, INC. | $21.48 | 2025 | Neffy |
| Seqirus USA INC | $16.95 | 2025 | Flucelvax |
| Collegium Pharmaceutical, INC. | $14.29 | 2025 | Jornay Pm |
| Astrazeneca Pharmaceuticals LP | $13.90 | 2024 | Flumist Quadrivalent |
| Advanced Respiratory, INC | $11.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Rose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.